Korro Bio's Pivot to GaINac Pragmatic After 'Disappointing' KRRO-110 Data, RBC Says

MT Newswires Live11-13

Korro Bio's (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragmatic approach after the "disappointing" data on its KRRO-110 product candidate, RBC Capital Markets said in a note Thursday.

The company is going into cash preservation mode by cutting its workforce by 34% across all levels in a bid to extend its cash runway for the development of KRRO-121, its next candidate as a potential treatment for patients with hyperammonemia.

Management also announced that it targets to a nominate a GalNAc-conjugated construct development candidate for alpha-1 antitrypsin deficiency, or AATD, in H1 2026.

"While the initial approach to AATD did not pan out, we think moving to GaINac makes logical sense," analysts said.

RBC downgraded Korro Bio to sector perform from outperform, and slashed its price target to $8 from $85 previously.

Shares of Korro Bio were down more than 76% in recent premarket activity Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583567596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583567596","market":"hk","top_or_hot":-1,"title":"Korro Bio's Pivot to GaINac Pragmatic After 'Disappointing' KRRO-110 Data, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a>'s (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragmatic approach after the \"disappointing\" data on its KRRO-110 product candidate, RBC Capital Markets said in a note Thursday.</p><p>The company is going into cash preservation mode by cutting its workforce by 34% across all levels in a bid to extend its cash runway for the development of KRRO-121, its next candidate as a potential treatment for patients with hyperammonemia.</p><p>Management also announced that it targets to a nominate a GalNAc-conjugated construct development candidate for alpha-1 antitrypsin deficiency, or AATD, in H1 2026.</p><p>\"While the initial approach to AATD did not pan out, we think moving to GaINac makes logical sense,\" analysts said.</p><p>RBC downgraded Korro Bio to sector perform from outperform, and slashed its price target to $8 from $85 previously.</p><p>Shares of Korro Bio were down more than 76% in recent premarket activity Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio's Pivot to GaINac Pragmatic After 'Disappointing' KRRO-110 Data, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio's Pivot to GaINac Pragmatic After 'Disappointing' KRRO-110 Data, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-13 20:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a>'s (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragmatic approach after the \"disappointing\" data on its KRRO-110 product candidate, RBC Capital Markets said in a note Thursday.</p><p>The company is going into cash preservation mode by cutting its workforce by 34% across all levels in a bid to extend its cash runway for the development of KRRO-121, its next candidate as a potential treatment for patients with hyperammonemia.</p><p>Management also announced that it targets to a nominate a GalNAc-conjugated construct development candidate for alpha-1 antitrypsin deficiency, or AATD, in H1 2026.</p><p>\"While the initial approach to AATD did not pan out, we think moving to GaINac makes logical sense,\" analysts said.</p><p>RBC downgraded Korro Bio to sector perform from outperform, and slashed its price target to $8 from $85 previously.</p><p>Shares of Korro Bio were down more than 76% in recent premarket activity Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRRO","symbol_name":"Korro Bio, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2583567596","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583567596","pubTimestamp":1763036954,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Korro Bio's (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragmatic approach after the \"disappointing\" data on its KRRO-110 product candidate, RBC Capital Markets s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRRO":"Korro Bio, Inc.","BK4139":"生物科技"},"translate_title":"RBC表示，在KRRO-110数据“令人失望”后，Korro Bio转向GaINac务实","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":1.5},"content_text":"Korro Bio's (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragmatic approach after the \"disappointing\" data on its KRRO-110 product candidate, RBC Capital Markets said in a note Thursday.The company is going into cash preservation mode by cutting its workforce by 34% across all levels in a bid to extend its cash runway for the development of KRRO-121, its next candidate as a potential treatment for patients with hyperammonemia.Management also announced that it targets to a nominate a GalNAc-conjugated construct development candidate for alpha-1 antitrypsin deficiency, or AATD, in H1 2026.\"While the initial approach to AATD did not pan out, we think moving to GaINac makes logical sense,\" analysts said.RBC downgraded Korro Bio to sector perform from outperform, and slashed its price target to $8 from $85 previously.Shares of Korro Bio were down more than 76% in recent premarket activity Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583567596","isCrawlerRequest":true}